🔍
Multi-epitope Fusion Antigen Vaccine for ETEC
Case ID:
C12168
Report of Invention:
9/17/2012
Web Published:
4/6/2020
Unmet Need:
Enterotoxigenic Escherichia coli (ETEC) is the leading cause of diarrheal diseases worldwide but to date no effective vaccine exists due to the heterogeneity in ETEC strains. There is a need for a vaccine that elicits a broad yet productive immune response against multiple ETEC antigens to provide protection.
Technical Details:
Researchers at Johns Hopkins University and South Dakota State University have developed a multi-epitope fusion antigen (MEFA) as a vaccine candidate to elicit protection against a broad range of heterogeneous ETEC strains. The vaccine candidate incorporates a fusion polypeptide molecule engineered to express immunogenic epitopes from multiple colonization factor antigens (CFAs) to address the heterogeneity in ETEC strains. In addition, the candidate includes covalently linked fragments of ETEC enterotoxins (toxoids) heat-labile toxin (LT) and heat-stable toxin (STa).
As shown in mice, the vaccine candidate is able to induce antibody responses to all CFA and toxoid antigens incorporated in the fusion polypeptide, indicating that the novel construct is immunogenic for all epitopes. Importantly, in addition to a serum IgG response, the vaccine induced mucosal IgA production crucial for control of ETEC at the intestinal site of infection.
Value Proposition:
Novel vaccine candidate for broad protection against heterogeneous ETEC strains
Enhanced protection without adverse effects of administration with toxoid inclusion strategy
Vaccine candidate can be administered alongside current therapeutic strategies
Looking for Partners to:
Develop & commercialize the technology as a novel vaccine candidate against ETEC infection and diarrheal disease.
Stage of Development
: Pre-clinical
Data Availability:
In vivo
mouse model
Inventors:
David Sack, Weiping Zhang
Patent Status:
Pending US application:
20160317638A1
Publication(s):
Ruan X, Sack DA, Zhang W. (2015). Genetic fusions of a CFA/I/II/IV MEFA (multiepitope fusion antigen) and a toxoid fusion of heat-stable toxin (STa) and heat-labile toxin (LT) of Enterotoxigenic Escherichia coli (ETEC) retain broad anti-CFA and antitoxin antigenicity. Plos One 10(3): e0121623.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
MULTIEPITOPE FUSION ANTIGENS AND VACCINES AND THEIR USE IN TREATMENT OF ENTEROTOXIGENIC DIARRHEA
PCT: Patent Cooperation Treaty
United States
15/105,195
10,646,560
6/16/2016
5/12/2020
12/17/2034
Granted
MULTIEPITOPE FUSION ANTIGENS AND VACCINES AND THEIR USE IN TREATMENT OF NTEROTOXIGENIC DIARRHEA
CON: Continuation
United States
16/858,924
11,684,661
4/27/2020
6/27/2023
12/17/2034
Granted
MULTIEPITOPE FUSION ANTIGENS AND VACCINES AND THEIR USE IN TREATMENT OF NTEROTOXIGENIC DIARRHEA
DIV: Divisional
United States
16/869,123
11,400,146
5/7/2020
8/2/2022
12/17/2034
Granted
Direct Link:
https://jhu.technologypublisher.com/technology/39495
Inventors:
Category(s):
Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities,
Get custom alerts for techs in these categories/from these inventors:
Subscribe for JHTV Updates
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
Bookmark this page
Download as PDF
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum